ADC Therapeutics announces presentation of LOTIS-7 clinical trial data at the European Hematology Association 2025 congress (EHA2025) and the 18th international conference on malignant lymphoma (ICML)

CAR-T Digest - August 2020

Weekly Digest - May 2025

14 May 2025: ADC Therapeutics announces presentation of LOTIS-7 clinical trial data at the European Hematology Association 2025 congress (EHA2025) and the 18th international conference on malignant lymphoma (ICML)

LOTIS-7 trial combining Zynlonta and Glofitamab in relapsed/refractory DLBCL showed a 5% overall response rate (ORR) and 90.9% complete response (CR) in 22 evaluable patients
Safety profile was consistent with individual agents; most common Grade ≥3 adverse event was neutropenia (32.3%)
Cytokine release syndrome (CRS) and ICANS were mostly low grade; no Grade ≥3 events reported
Updated data to be presented at EHA2025 and ICML
ZYNLONTA continues to show promise in combination therapies for aggressive B-cell malignancies